Abstract.
Improving the quality of ulcer healing (QOUH) is one of the valid methods of prevention of relapse of gastric ulcers. We investigated the effect of lafutidine on the QOUH of gastric ulcer compared with famotidine in a randomized, multi-centre controlled trial. Consecutive 80 patients with a gastric ulcer were randomly assigned to receive twice daily either lafutidine (10 mg) or famotidine (20 mg) for 12 weeks. Esophagogastroduodenoscopy was performed to examine the ulcer healing rate and rate of fl at type ulcer scars using dye-contrast. The gastric ulcer healing rate was 92.1% in the lafutidine group (35/38) and 94.7% in the famotidine group (36/38). The rate of flat-type ulcer scars was significantly higher in the lafutidine group (68.4%, 26/38) than in the famotidine group (42.1%, 16/38) (P = 0.021). In conclusion, the present study demonstrated that lafutidine, as compared to famotidine, yields a signifi cantly superior QOUH in patients with gastric ulcers in the clinical setting.
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
Additional information
Received and accepted 3 August 2006
Rights and permissions
About this article
Cite this article
Higuchi, K., Watanabe, T., Tominaga, K. et al. Lafutidine can improve the quality of gastric ulcer healing in humans: a randomized, controlled, multicenter trial. Inflammopharmacol 14, 226–230 (2006). https://doi.org/10.1007/s10787-006-0299-0
Issue Date:
DOI: https://doi.org/10.1007/s10787-006-0299-0